the field force was told to sell the larger tube sizes because taro feared that fugera and perrigo would cause an extreme drop in their .25 cream sales. this initiative started in jan of 2010. sales was told by mgt. that they would be paid $ per tube, because they felt if they incented sales to sell larger tubes only - where there is no generic substitution possible - they could hold on to their market share. They were correct - taro's desoxi molecule remained flat for sales for time period of 2009 vs 2010. They should have lost tens of millions to fougera and perrigo, as they both had better price at the pharmacy, and were actively switched at the pharmacy due to financial incentives from taro's desoxi all year long.
The sales force fought hard, secured thousands and thousands of new scripts, and maintained the desoxi market share in a year that otherwise would had been catastrophic for the .25 cream market share. As a result, many reps earned thousands of dollars in compensation according to the incentive contract.
Sales management decided revoke the entire bonus, citing "flat sales" as a justification. "Flat sales" was actually a remarkable achievement - but they used it to justify the revocation of bonus.
Current bonus plan, compensation structure and marketing directive is now unknown.